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ABSTRACT 
The prevalence of antidepressant use is increasing. Past studies have reported that the use of 
antidepressants can influence cardiovascular risk factors including obesity, blood lipids and 
blood pressure (BP). However, because antidepressants have the potential to influence both 
body weight and cardiovascular disease (CVD) risk, it is currently unclear if antidepressant use 
alters CVD risk independent of obesity. Therefore, the aim of this manuscript was to examine if 
the type of antidepressant (Selective-Serotonin Reuptake Inhibitors (SSRIs) or Tricyclic 
antidepressants (TCAs)) used influenced the association between obesity and CVD risk. This 
study demonstrated that for a given body mass index (BMI) certain antidepressant use was 
associated with exacerbated health risk factors and CVD risk. Clinically, this may indicate that 
the differences in body weight observed with the use of SSRIs and TCAs may not be associated 
with the normally expected differences in cardiovascular risk. 
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1.0 GENERAL INTRODUCTION 
Depression is one of the leading causes of disease world-wide (1). This is not only concerning 
due to the negative personal consequences for the individual but also due to the high economic 
costs. Financial costs associated with depression are not only a result of its treatment but also 
the healthcare costs required due to comorbidities associated with depression (2). Mood 
disorders are characterized by both mental and physical adverse effects (3). Psychologically 
depressive disorders are associated with feelings of sadness, anxiety, fatigue and an inability to 
feel pleasure in addition to increased frequency of suicidal thoughts (3, 4). Physically, 
depression increases the risk of developing chronic conditions such as coronary artery disease 
(CAD), cancer, stroke, epilepsy, alzheimers disease and diabetes between 1.3 to 6 fold (5). 
Beyond the increased risk of comorbidities, mood disorders are also linked with increased 
mortality risk and poorer quality of life (5, 6).  
In order to lessen the negative consequences associated with depression, medicinal 
treatment is often advised (1, 3). In the 1950s doctors began regularly prescribing 
antidepressants after the chemical manipulation of antihistamines and tuberculosis medications 
revealed desirable psychotropic properties (3, 7). It was soon discovered that these early forms 
of antidepressants positively influenced the nervous system of patients with psychopathologies 
(3). However, early antidepressants were poorly understood biologically and therefore were 
often linked with significant health and safety concerns. More recently, through improved 
understanding of biological mechanisms antidepressants have been found to be safe and 
efficacious at treating depression (3). Yet, globally less than half of those diagnosed with 
depression receive antidepressant medication (8). There are no concrete answers as to why 
such a large proportion of patients with depression are not receiving treatment however current 
hypotheses include fear of side effects and suicide risks, insufficient insurance coverage, lack of 
access to mental health treatment and concerns over drug-drug interactions (3, 8). Regardless, 
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antidepressant medications use is increasing overall and they are now one of the most 
prescribed types of medications in the United States (U.S.) (9, 10). In addition, there is also a 
rising trend in the number of prescriptions patients are receiving once they begin medicinal 
treatment (11). 
Antidepressants can be used to treat a wide variety of illnesses but are used most often 
for depression (65%) and anxiety (16%) (9). SSRIs and TCAs are two of the most frequently 
prescribed antidepressants on the market today (11). As with many medications, SSRIs and 
TCAs have differential side effect profiles, interactions and ease of use (12). Antidepressants 
have been reported to inadvertently interact with other drugs, particularly alcohol, and some 
foods (3). Furthermore, certain antidepressants like SSRIs and TCAs influence factors linked 
with changes in cardiovascular health such as body weight (13–22), blood lipids (23–29)  and  
BP (28, 30–32).  
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2.0 REVIEW OF RELATED LITERATURE 
Prevalence of Depression 
The prevalence of depression has decreased in the U.S. over the past couple of years, 
yet the percentage of people receiving treatment for mental health conditions has increased 
(11). Thus, it is likely not that there is a higher incidence of depression but merely that more 
people are seeking treatment (11). This upward trend in treatment is due to the accumulation of 
many factors such as increased awareness surrounding the need for mental health treatment, 
promotion of mental health awareness and broadening public acceptance of mental health 
disorders (11). Within the U.S. depression occurs more often in women (3), people of young age 
groups (18-44 years of age) and divorcees (33). Furthermore, depressive disorders are more 
frequent in people of low socioeconomic status, limited education and those who are disabled 
(33).  
Types of Psychotropic Medications and Mechanisms of Action 
Psychotropic medications are inclusive of anxiolytics, antipsychotics, stimulants, mood 
stabilizers and antidepressants (11). Antidepressant medications can then be further subdivided 
into many types of antidepressants such as monoamine oxidase inhibitors (MAOIs), Tricyclic 
antidepressants (TCAs), Selective-Serotonin Reuptake Inhibitors (SSRIs), Norepinephrine 
Reuptake Inhibitors (NRIs), Norepinephrine Dopamine Reuptake Inhibitors (NDRIs) and 
numerous other agents (34). Antidepressants target receptors and neurotransmitters in the 
nervous system in order to improve brain chemistry (12, 34). Neurotransmitters are naturally 
produced chemical messengers stored in neurons throughout the body and released by the 
nervous system (3). Once activated neurotransmitters leave their neurons, travel through a 
synapse and attach to specific receptors at other cells or neurons in order to generate their 
biological effects (3). After neurotransmitters complete their desired task they can either be 
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degraded or taken back into the neuron(s) they were released from, a process known as 
reuptake (3). Antidepressants can act to either alter the breakdown of the neurotransmitters 
themselves or influence their reuptake (4, 7). For example, TCAs inhibit the reuptake of 
serotonin, norephinephrine (NE), and dopamine while SSRIs inhibit the reuptake of only 
serotonin (12). Newer antidepressants, like SSRIs, are able to selectively alter the function of 
particular neurotransmitters while some of the older medications such as MAOIs and TCAs 
have less selective mechanisms of action within the brain (12). Consequently, older 
antidepressants tend to be linked with a greater number of side effects than some of the newer 
antidepressants (12).  
Blood Pressure 
The use of antidepressant medications has been connected to both hypotension and 
hypertension, depending on the type of antidepressant, through alterations to sympathetic 
activation (28, 30–32). SSRIs are reported to have inhibitory effects on the sympathetic nervous 
system, consequently lowering mean arterial pressure (32). Contrastingly, resting hypertension 
experienced with TCA use has been attributed to their norepinephrine (NE) re-uptake blocking 
properties which is indicative of increases in sympathetic activation (28, 30, 32), or increases in 
BMI typically observed with their use (13–17). Differences in the activation of the sympathetic 
nervous system is of great clinical importance given that sympathetic stimulation has been 
linked to increased risk of cardiovascular and metabolic disease in patients with 
psychopathological disorders (32). This study will assist in delineating whether or not the 
hypertensive effects of TCAs that were previously noted in the literature are independent of 
BMI, therefore suggesting the differences may be due to alterations in autonomic function. 
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Glycemic Control 
SSRI use is often connected with hypoglycaemia and favourable insulin sensitivity (23, 
35–37) while glycaemic dysfunction is often associated with TCA use (16, 23, 35, 37–40). In 
approximately two-thirds of case reports variations in glycaemic indicators are reported within 
one month of beginning treatment (37). Short-term treatment, three months, with SSRIs has 
been observed to enhance insulin sensitivity thus increasing the prevalence of hypoglycaemia 
(36). In contrast, long-term treatment with TCAs has been linked with an 84% increase in the 
risk of diabetes (38). The hyperglycaemic effects associated with the use of TCAs has been 
linked with numerous mechanisms such as weight gain, elevated cortisol levels due to 
hypothalamo-pituitary-adrenal axis (HPA-axis) dysregulation, as well as their NE re-uptake 
blocking properties consequently stimulating gluconeogenesis and glycogenolysis (36). 
Furthermore, the hyperglycemic effects associated with TCA use do not only increase a 
patient’s risk of diabetes but insulin resistance has also been hypothesized to increase 
triglyceride (TG) levels independent of obesity (41, 42).   
Blood Lipids and Inflammation 
Past studies have linked depression with obesity (13) and inflammation (28, 43, 44), 
which are both factors in development of dyslipidemia (23, 27, 29, 45, 46), as well as the 
pathogenesis of heart failure coronary artery disease (CAD) (47, 48). Some studies observed 
SSRIs to have beneficial effects on lipid homeostasis (23–25), while another study has reported 
a negative SSRI influence (26), though these changes tended to be highly correlated with 
changes to body weight (26). However, SSRI use has been associated the decreased 
productions of inflammatory markers (28, 43, 49) which could prompt positive changes to lipid 
homeostasis regardless of BMI. In contrast, TCA use is connected with inflammation (28) and 
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hypertriglyceridemia both of which are frequently attributed to weight gain and specifically 
increased intra-abdominal fat (27–29). In literature to date, it is unclear if the use of 
antidepressants is connected with changes to lipid homeostasis independent of BMI.  
Cardiovascular Risk 
The increased mortality rate seen in mood disorder patients has largely been attributed 
to the increased prevalence of cardiovascular disease (CVD), which has been commonly 
associated with the metabolic syndrome (28, 50). Although depression and CVD are frequently 
linked (30, 48, 51, 52), research on antidepressant usage in relation to prevalence of CVD is 
divided (32, 52). This is likely due to the wide range of cardiac factors that antidepressants 
could influence, including BMI, autonomic regulation, BP and cholesterol levels. Even though 
obesity and weight gain are clearly associated with increased cardiovascular risk (48, 53), it is 
uncertain if antidepressant use influences the association between obesity and CVD risk. Thus, 
the aim of this thesis is to examine if the type of antidepressant used (SSRIs/TCAs) influences 
the association between obesity and CVD risk. 
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3.0 MANUSCRIPT 
3.1 BACKGROUND 
 
The current prevalence of depression is between 8 to 12% worldwide (54). Beyond the 
increased risk of coronary artery disease (CAD), cancer, stroke, epilepsy, alzheimers disease, 
diabetes (5) and all cause mortality, mood disorders have also been linked to poorer quality of 
life (5, 6) and increased likelihood of obesity (13). Since the mid-1990’s the use of 
antidepressants in the U.S. has increased substantially (11). The prevalence of SSRIs has risen 
from 55 to 67% of all antidepressant prescriptions, while the use of TCAs has decreased from 
35 to 11% (11). Even though the use of TCAs has decreased over recent years they are 
reported to have a greater efficacy at treating certain types of depression such as melancholic 
and psychotic (3). Given that psychopathological patient care is becoming increasingly 
individualized it is still of clinical importance to research TCAs since it is likely they will continue 
to be prescribed both now and in the future (3). 
SSRIs and Tricyclics are also commonly used for a wide range of syndromes including 
anxiety, attention deficit, nervous system disorders and other non-psychiatric disorders (9). 
Antidepressant use has been associated with a one to three kg weight gain in 10 to 40% of 
patients receiving pharmaceutical treatment (14). However, the different classes of 
antidepressants are reported to influence body weight differently (13–15). Short-term use of 
SSRIs is associated with weight loss (18–21) while weight restoration, or gain occurs with long-
term use (13, 16, 22). On the other hand, long-term treatment with TCAs has been more 
frequently linked with weight gain (13–17). Furthermore, TCAs have been linked with 
hypertriglyceridemia (27, 29) and both TCAs and SSRIs have been associated with blood 
pressure (BP) dysregulation (28, 30–32). However, because antidepressant use influences both 
body weight and CVD risk it is currently unclear if antidepressant use alters CVD risk 
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independent of obesity. Thus, the objective of this study is to determine if the type of 
antidepressant used (SSRIs/TCAs) influences the association between obesity and CVD risk.  
9 
 
3.2 METHODS & PROCEDURES 
 
Participants 
The sample included 96 154 participants from the NHANES. NHANES is a cross-sectional study 
that is a U.S. nationally representative survey which utilizes a multistage probability cluster 
design. The National Center for Health Statistics (NCHS) of the Centers for Disease Control and 
Prevention (CDC) collects the data through interviews, physical examinations and laboratory 
tests. Prior to examination, all participants gave their informed written consent and study 
protocol was approved by NCHS. Further details pertaining to study design and methods have 
been previously reported (55, 56). 
NHANES III (1988-1994) and NHANES continuous data (1999-2010) were combined to 
provide sufficient sample size for the analysis of different subclasses of antidepressant use. 
Participants were excluded from the data set if they were under 18 years of age (n = 41 198), if 
they were pregnant (n = 1 196) or they had a BMI <15 kg/m2 or >70 kg/m2 (n = 768). 
Additionally, participants with missing data for BMI (n = 18 133), antidepressant use (n = 14), 
SBP (n = 38 512), DBP(n = 39 576), HDL(n = 30 809), TGs (n = 56 127), fasting plasma 
glucose (FPG: n = 63 849), glycohemoglobin (HbA1c: n = 36 994), insulin (n = 64 244), HOMA-
IR (n = 64 336), chronic disease (cancer: n = 43 723, diabetes: n = 16 942, CVD: n = 43 866, 
obstructive respiratory disease: n = 43 798), smoking status (n = 43 704) and dietary 
information were not included (carbohydrates (CHO): n = 12 724, fat: n = 12 478). This left 18 
274 eligible participants. 
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Survey Methods  
Age, gender, ethnicity (white, black, other), poverty-income-ratio (income, scored one to five), 
medication use (user/non-user), smoking status (current smoker/non-smoker) and physical 
activity (PA) status were assessed by individual questionnaire. Income score is calculated as 
the family earnings divided by the poverty guidelines provided by the Department of Health and 
Human Services (HHS). If income was missing, mean substitution was performed. PA was 
coded as: moderate intensity greater than or equal to one time of moderate intensity PA / week; 
or vigorous intensity greater than or equal to one time of vigorous intensity PA /week; or inactive 
(zero min of moderate or vigorous PA /week). Moderate PA was defined as a metabolic 
equivalent (MET) score between three and six while vigorous PA was a MET score greater than 
six. When individuals performed both moderate and vigorous PA they were classified as 
vigorous PA. If the participant reported doing no physical activity they were recorded as inactive. 
In NHANES III blood lipids and glycemic indicators were measured using standard procedures 
after a 10-16 hour fast prior to morning testing or after a six hour fast for afternoon/evening 
tests. In NHANES 1999-2004 participants were asked to fast for 8 to 24 hours and greater than 
or equal to nine hours for NHANES 2005-2010. Any additional details on blood lipid or glycemic 
measurement techniques can be found elsewhere (55, 56). Chronic disease history was 
obtained through self-reported doctor diagnoses of cancer, diabetes and CVD (yes/no). CVD 
was a history of heart failure, angina, or stroke in NHANES III and a history of heart failure, 
angina, stroke, myocardial infarction or coronary heart disease in NHANES 1999 to 2010. A 24-
hour dietary recall interview was also performed to obtain dietary information on CHOs and fat 
(grams, gm). 
 
A minimum of three BP (mmHg) readings were taken by trained BP technicians. 
Anthropometric measures such as weight, height and BMI were also assessed by trained health 
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technicians at the mobile examination center. Self-reported height and weight were used to 
substitute missing BMI data in NHANES III.  
 
Prescription Medication Categorization 
Data on prescription medication use was obtained through household interviews. Type of 
prescription medication usage within the last 30 days was recorded. Whenever possible the 
prescription container was examined by the interviewer. In NHANES III the medications were 
assigned a four-digit code based on the National Drug Directory of the Food and Drug 
Administration (FDA). In NHANES continuous the Lexicon Plus ® system was used to sort 
medications by therapeutic classification and drug ingredients. The two most common 
antidepressant drug categories were analyzed in this study: 1) Selective-Serotonin Reuptake 
Inhibitors (SSRIs; n=219) and 2) Tricyclic antidepressants (TCAs; n=116). 
 
Statistical Analysis 
Demographic characteristics were stratified by user and non-user for each antidepressant type. 
Continuous variables are shown as a mean ± standard deviation (SD). Categorical variables are 
presented as sample size (n) and prevalence (%). Group differences in continuous variables 
were analyzed using t-tests and chi-square tests (x2) were used for categorical variables. Linear 
regression analyses were used to examine the influence of antidepressant usage on the 
association between BMI and health risks using first order drug and BMI interaction and main 
effect (ME) terms. The odds ratio (OR, 95% confidence interval (CI)) of prevalent chronic 
disease was assessed using logistic regression. All regression analyses were adjusted for age, 
sex, ethnicity, income, smoking status, PA, as well as dietary CHOs and fat intake. Further 
adjustment for prevalent CVD was performed when assessing blood pressure and blood lipids 
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while diabetes status was adjusted for when analyzing glycemic markers. Due to the 
amalgamation of continuous and NHANES III data sets, weighted adjustments could not be 
used. All analyses were completed with SAS (ver. 9.2). Statistical significance was defined as 
P<0.05.  
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3.3 RESULTS 
 
Participant Characteristics 
Participant characteristics are shown in Table 1. Age did not differ by SSRI use (P>0.05), while 
individuals using TCAs were older than their non-user counterparts (P<0.05). Individuals taking 
SSRIs and TCAs were more likely to be female than non-users (P<0.05). Those taking SSRIs 
had a 1.0±6.3 kg/m2 higher BMI than non-users (P<0.05) with no difference by TCA use 
(P>0.05). SSRI users had a 0.4±1.6 higher income while TCA users had a 0.4±1.4 lower income 
than their respective non-users (P<0.05). PA levels did not differ by SSRI use (P>0.05), while 
TCA users had significantly lower PA levels than those not using TCAs (P<0.05). 
Individuals taking SSRIs had a higher prevalence of CVD, 4±20 mmHg lower SBP, 2±12 
mmHg lower DBP and 0.09±0.44 mM higher HDL than those not using SSRIs (P<0.05). Those 
using TCAs had a higher prevalence of diabetes and CVD, 7±21 mmHg higher SBP, 4±10 
mmHg higher DBP, 0.28±1.07 higher TG and 1.6±8.0 higher HOMA-IR than those not using 
TCAs (P<0.05). There were no significant differences (P>0.05) in smoking status, CHO or fat 
intake, FPG and HbA1c by SSRI or TCA use. 
Cardiovascular Disease Risk Factors 
For a given BMI, individuals taking SSRIs tended to have significantly better health risk profiles 
with lower SBP (P=0.002), marginally lower DBP (P=0.056) and higher HDL (P=0.003) 
compared to non-users (Table 2) with adjustment for age, sex, ethnicity, income, smoking 
status, PA, total CHOs and fat intake and CVD. Conversely, those who used TCAs had 
significantly (P<0.05) worse health risk profiles with higher DBP and TGs as compared to non-
users for a given BMI (Table 2). Insulin resistance (HOMA-IR) was higher in TCA users and 
those with larger BMIs, whereby the differences in insulin resistance between TCA users and 
non-users was greater with higher BMIs (Interaction Effect: P=0.013; Figure 1). 
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Likelihood of Chronic Disease 
Neither SSRIs nor TCAs significantly altered the relationship between BMI and cancer (P= 0.30 
and P= 0.49 respectively, results not shown). However, individuals taking SSRIs were less likely 
to have prevalent CVD than non-users (OR, 95% CI= 0.50, 0.33-0.75) for a given BMI, with no 
differences by TCA use (OR= 0.74, 0.44-1.24) (Figure 2).  
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3.4 DISCUSSION 
 
The findings from this study demonstrate that for a given BMI, antidepressant use is associated 
with differences in health risk factors and CVD risk. Individuals who used SSRIs tended to have 
a better cardiometabolic profile, while TCA users generally had a worse cardiometabolic profile 
than was expected given their BMI. Clinically, this may suggest that the differences in body 
weight observed with antidepressant use may not be associated with the normally expected 
differences in cardiovascular risk. 
Antidepressant use has been linked to both hypotension and hypertension, depending 
on the type of antidepressant, through alterations to sympathetic activation (28, 30–32). SSRIs 
are reported to have inhibitory effects on the sympathetic nervous system, consequently 
lowering mean arterial pressure (32). Contrastingly, TCA use was associated with significantly 
higher resting DBP for a given BMI. Increases in BP with TCA use could be attributed to the 
blocking of noradrenaline (NE) re-uptake which is indicative of increases in sympathetic 
activation (28, 30, 32), or increases in BMI typically observed with their use (13–17). However, 
the hypertensive effects of TCAs were observed independent of BMI, suggesting these 
differences may be due to alterations in autonomic function. Therefore, both SSRIs and TCAs 
differentially influence blood pressure independent of body weight. 
Past studies have linked depression with obesity (13) and inflammation (28, 43, 44, 57), 
which are both factors in development of dyslipidemia and decreased HDL (23, 27, 29, 45, 46), 
as well as the pathogenesis of heart failure and coronary artery disease (CAD) (47, 48). 
However, SSRI use has been linked with decreased production of inflammatory markers (43, 
49), and may potentially explain why SSRI use was associated with higher HDL levels, with and 
without adjustment for BMI.  In contrast, TCA use is often connected with hypertriglyceridemia 
that is commonly attributed to weight gain (27, 29). We extend previous research (27, 29) by 
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demonstrating the association between TCA use and hypertriglyceridemia is truly independent 
of BMI. The association between TCAs and hypertriglyceridemia may be due to the higher 
insulin resistance observed in TCA users. Insulin resistance has been hypothesized to increase 
TG levels independent of obesity (41, 42). Thus, our findings suggest that antidepressant use 
influences blood lipids and insulin sensitivity independent of body weight. 
Although depression and CVD are frequently linked (30, 48, 51, 52), research on 
antidepressant usage in relation to prevalence of CVD is divided (32, 52). This is likely due to 
the wide range of cardiac factors that antidepressants can influence, including autonomic 
regulation, BP and cholesterol levels. We observed that SSRI use was associated with lower 
SBP for a given BMI. Though four mmHg lower SBP may appear to be a small magnitude, this 
magnitude of decrease has been related to an 19% lower incidence of stroke and 14% lower 
incidence of ischemic heart disease (IHD)(58). Conversely, a four mmHg higher DBP observed 
with TCA use has been linked with a 16 to 21% increase in the incidence of CAD (59). 
Therefore, SSRI and TCA use may be associated with differential and clinically relevant 
changes in CVD risk independent of BMI. 
This study had limitations and strengths. The data is from cross-sectional surveys and 
these results do not allow one to infer causation. Moreover, due to combining of NHANES III 
and continuous data, the results are not representative of the current U.S. population. It is also 
worth noting that we investigated two agents that are commonly prescribed as antidepressants 
but did not strictly examine depressive disorders. SSRIs and TCAs are used for an array of both 
psychiatric and non-psychiatric disorders and we were unable to ascertain what condition(s) the 
medications were specifically prescribed for. A strength was the use of chronic disease history 
data collected through personal interviews which has been shown to generate a low cognitive 
burden on survey respondents and produce a low recall bias when compared to  self-
administered questionnaires (60). Another key strength was the rigorous adjustment for 
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numerous confounding variables that have been shown to be associated with CVD risk in 
addition to adjustments for prevalent chronic conditions in order to reduce potential bias from 
previously established indications and contraindications for each antidepressant. 
In summary, for a given BMI when compared against non-users, SSRI users tended to 
have a better cardiometabolic profile, while TCA users generally had a worse cardiometabolic 
profile. Future longitudinal studies are needed to explore and test for causal relations. When 
health professionals are prescribing antidepressant medications, further consideration should be 
given to the cardiovascular risk profile of individual patients.
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3.5 GENERAL CONCLUSION 
 
Regular treatment of mental disorders began in the early 1900’s (7). Initially the treatment of 
mental health issues was very intrinsic and primitive including techniques such as lobotomy and 
electroshock therapy (3). However, within just a couple of decades psychopharmaceuticals 
were derived and quickly became a primary treatment choice replacing these more drastic 
measures (3). MAOIs were one of the first antidepressants to hit the market with TCAs following 
shortly after, by the 1970’s-1990’s SSRIs gained popularity and became the medication of 
choice (3, 7). At the beginning of the 90’s newer generation antidepressants such as SNRIs 
started to be developed and distributed (7). Since then, development of more effective 
antidepressants that differentiate themselves from previous medications has been lacking (61). 
It is probable that the short-comings of pharmaceutical companies to develop newer fasting 
acting products with fewer side effects is partially a result of decreasing profitability due to 
patents expiring and consequently increased generic availability (61). Furthermore, the 
treatment of depression is complicated given that the biological mechanisms behind depression 
are still not fully understood (61). 
Currently, depression is considered a severe global health concern with World Health 
Organization (WHO) figures indicating a prevalence of 350 million people afflicted worldwide 
(61). The preliminary stages of treatment with antidepressants can be frustrating given that 
approximately two-thirds of patients do not respond to initial treatment (4, 61). The process of 
treatment response is also time consuming with most antidepressants taking weeks to month 
before therapeutic responses become noticeable (4). However, once the appropriate medication 
is determined antidepressants are effective in treating 80 to 90% of patients with moderate to 
severe depression (3, 61). Yet, fewer than 50% of those with depressive disorders receive 
medicinal treatment with some populations below 10% (8). The low use of antidepressants has 
been attributed to a lack of access to sufficient treatment, the social stigma attached to mental 
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health disorders, increased risk of suicide and side effects obtained from antidepressant use (3, 
8, 61). Although antidepressant use has been reported to come with undesirable consequences 
such as weight changes (13–22) and worsened cardiovascular risk factors (23–32), the risk of 
suicide is far greater in patients with untreated depression than when medicinally treated (51). 
Further, this thesis demonstrates that users of certain antidepressants have a better 
cardiometabolic profile for a given BMI. Clinically, this may suggest that the differences in body 
weight observed with antidepressant use may not be associated with the normally expected 
differences in cardiovascular risk. Thus, when prescribing antidepressant medications further 
consideration should be given to the cardiovascular risk profile of individual patients. These 
recommendations coincide with previous suggestions that psychopathological patient care 
needs to be further individualized in order to best support patients. 
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Continuous data as mean±SD and categorical data presented as n (%) within’ Use category’. 
SSRIs, Selective-Serotonin Reuptake Inhibitors; TCAs, Tricyclic antidepressants; N, sample size; BMI, 
body mass index; Income, poverty-income ratio; CHO, carbohydrates; CVD, cardiovascular disease; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein cholesterol; 
TGs, fasting serum triglycerides; FPG, fasting plasma glucose; HOMA-IR, homeostatic model 
assessment of insulin resistance; HbA1c, glycohemoglobin. 
P<0.05, significantly different from non-users within that drug category.
Table 1. Characteristics of participants, stratified by drug and use category 
 
Drug Category                  SSRIs                     TCAs 
Use Category Non-User User P-value Non-User User P-value 
n (%) 18 055 (98.8) 219 (1.2)    18 158 (99.4) 116 (0.6)   
Age  (years) 49.3±18.5 51.2±15.4 0.06 49.2+18.5 58.5+17.6 <0.0001 
Sex (Female) 9 083 (50.3) 157 (71.7) <0.0001 9 160 (50.5) 80 (69.0) <0.0001 
BMI (kg/m
2
) 28.1±6.1 29.1±6.3 0.01 28.1±6.1 28.4±7.0 0.62 
Ethnicity             
White 8 474 (46.9) 159 (72.6) <0.0001 8 569 (47.2) 64 (55.2) 0.17 
Black 3 898 (21.6) 15 (6.9)  3 889 (21.4)  24 (20.7)   
Other 5 683 (31.5) 45 (20.6)   5 700 (31.4) 28 (24.1)   
Income (0-5) 2.5±1.5 2.9±1.6 0.001 2.5±1.5 2.1±1.4 0.003 
Smoking Status             
     Smoker 4 222 (23.4) 55 (25.1)  0.55 4 246 (23.4) 31 (26.7) 0.40  
Dietary Factors             
     CHO Intake (gm) 250±117 236±107 0.07 250±117 229±112 0.05 
     Fat Intake (gm) 77±43 74±36 0.20 77±43 72±49 0.33 
Physical Activity (≥1/wk)             
     Inactive 6 619 (36.7) 85 (38.8) 0.73 6 642 (36.6) 62 (53.5) <0.0001 
     Moderately active  9 126 (50.6) 109 (49.8)   9 184 (50.6) 51 (44.0)   
     Vigorously active 2 310 (12.8) 25 (11.4)   2 332 (12.8) 3 (2.6)   
Diabetes (%) 1 652 (9.2) 23 (10.5) 0.49 1 651 (9.1) 24 (20.7) <0.0001 
CVD 1 730 (9.6) 34 (15.5) 0.003 1 743 (9.6) 21 (18,1) 0.002 
Health Risk Factors             
     SBP (mmHg) 125±20 121±20 0.004 125±20 132±21 0.0002 
     DBP (mmHg) 72±11 70±12 0.002 72±11 76±10 0.0006 
     HDL (mM) 1.35±0.40 1.44±0.44 0.002 1.35±0.40 1.34±0.37 0.66 
     TG (mM) 1.57±1.05 1.56±0.88 0.82 1.57±1.05 1.85±1.07 0.004 
     FPG (mM) 5.8±1.8 5.7±1.5 0.52 5.8±1.8 6.0±2.6 0.30 
     HOMA-IR 3.4±3.9 3.9±5.2 0.16 3.4±3.9 5.0±8.0 0.04 
     HbA1c (%) 5.6±1.0 5.6±0.7 0.32 5.6±1.0 5.8±1.4 0.08 
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Table 2. The association of antidepressant usage on health risk factors by drug category 
Drug Category                                     SSRIs 
 Predicted LSM Value 
 Non-User User P-value 
SBP (mmHg) 125±1 121±1 0.002 
DBP (mmHg) 71±1 69±1 0.056 
HDL Cholesterol (mM) 1.34±0.005 1.41±0.02 0.003 
TG (mM) 1.57±0.01 1.50±0.07 0.32 
FPG (mM) 7.1±0.02 6.9±0.1 0.45 
HOMA-IR 5.0±0.05 5.3±0.2 0.14 
HbA1c (%) 
 
6.4±0.01 6.4±0.06 
 
0.49 
 
Drug Category TCAs  
 Predicted LSM Value  
 Non-User User P-value 
SBP (mmHg) 125±1 127±2 0.19 
DBP (mmHg) 71±1 75±1 <0.0001 
HDL Cholesterol (mM) 1.34±0.005 1.29±0.03 0.13 
TG (mM) 1.57±0.01 1.78±0.09 0.023 
FPG (mM) 7.1±0.02 6.9±0.1 
 
0.21 
HOMA-IR * * * 
HbA1c (%) 
 
6.4±0.01 6.3±0.08 0.35 
 
Predicted Least Square Adjusted Means (LSM±SEE) values are adjusted for: BMI, age, sex, ethnicity, 
income, smoking status, PA, total CHOs and fat intake. Further adjustment for CVD was performed when 
assessing blood pressure and blood lipids while diabetes status was adjusted for when analyzing 
glycemic markers. 
SSRIs, Selective-Serotonin Reuptake Inhibitors; TCAs, Tricyclic antidepressants; CVD, cardiovascular 
disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein 
cholesterol; TGs, fasting serum triglycerides; FPG, fasting plasma glucose; HOMA-IR, homeostatic model 
assessment of insulin resistance; HbA1c, glycohemoglobin; Income, poverty-income ratio; PA, physical 
activity; CHOs, carbohydrates. 
* Significant interaction effect (see Figure I). 
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Figure 1. The relationship between BMI and HOMA-IR in SSRI (A) and TCA (B) users. 
 
HOMA-IR. homeostatic model assessment of insulin resistance; BMI, body mass index; SSRIs, Selective-
Serotonin Reuptake Inhibitors; TCAs, Tricyclic antidepressants; INT, interaction; ME, main effect.  
Legend: solid line= SSRI or TCA user, dashed-line= SSRI or TCA non-user.  
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Figure 2. The relationship between BMI and CVD in SSRI (A) and TCA (B) users. 
OR, odds ratio; CVD, cardiovascular disease; BMI, body mass index; SSRIs, Selective-Serotonin 
Reuptake Inhibitors; TCAs, Tricyclic antidepressants; INT, interaction; ME, main effect. 
Legend: solid line= SSRI or TCA user, dashed-line= SSRI or TCA non-user. 
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